GXD-Bio Appeals Genetic Tester IP Loss Against Myriad
A South-Korean biotech firm has appealed a ruling in December that revoked its breast cancer test patent and dismissed its infringement claims against Myriad Genetics in Europe's patent court....To view the full article, register now.
Already a subscriber? Click here to view full article